Genfit (NASDAQ:GNFT) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Genfit (NASDAQ:GNFT) in a report issued on Friday, Benzinga reports. The brokerage currently has a $13.00 target price on the stock.

Genfit Stock Up 9.4 %

Shares of NASDAQ GNFT opened at $6.06 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.74 and a quick ratio of 3.74. The firm has a fifty day moving average of $4.58 and a 200-day moving average of $4.26. Genfit has a 52-week low of $2.97 and a 52-week high of $6.08.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.